@article{528d102a511d4552a45e33f7f3759438,
title = "ALSUntangled #63: ketogenic diets",
abstract = "ALSUntangled reviews alternative and off label treatments with a goal of helping patients make more informed decisions about them. Here we review ketogenic diets. We shows that these have plausible mechanisms, including augmenting cellular energy balance and reducing excitotoxicity, neuroinflammation and oxidative stress. We review a mouse model study, anecdotal reports and trials in ALS and other diseases. We conclude that there is yet not enough data to recommend ketogenic diets for patients with ALS, especially in light of the many side effects these can have.",
keywords = "Ketone, alsuntangled, ketogenic diet, mitochondria, therapy, transgenic animals",
author = "Richard Bedlack and Barkhaus, {Paul E.} and Benjamin Barnes and Morgan Beauchamp and Tulio Bertorini and Bromberg, {Mark B.} and Carter, {Gregory T.} and Vinay Chaudry and Merit Cudkowicz and Ce Jackson and Gleb Levitsky and Isaac Lund and Christopher McDermott and Steven Novella and Natasha Olby and Lyle Ostrow and Pattee, {Gary L.} and Terry Heiman-Patterson and Dylan Ratner and Kristiana Salmon and Susan Steves and Mark Terrelonge and Paul Wicks and Wills, {Anne Marie}",
note = "Funding Information: ALSUntangled is sponsored by the ALS Association. Richard Bedlack has research support from ALSA, Orion, MediciNova, and the Healey Center, and consulting support from AB Science, Alexion, ALSA, Amylyx, Biogen, Brainstorm Cell, Corcept, GenieUs, Guidepoint, ITF Pharma, Mallinkrodt, New Biotic, Orphazyme, and Woolsey Pharma. Publisher Copyright: {\textcopyright} 2021 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.",
year = "2021",
doi = "10.1080/21678421.2021.1990346",
language = "English (US)",
journal = "Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders",
issn = "2167-8421",
publisher = "Informa Healthcare",
}